Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy
Anti-Cancer Drugs,  Clinical Article

Zhao HY et al. – The results provide evidence that the thymidine phosphorylase (TP) expression may be a prognostic factor in breast cancer patients treated with capecitabine–based first–line chemotherapy, and βIII–tubulin can be used to predict the outcome of capecitabine in combination with taxanes as first–line chemotherapy. Therefore, these potential biomarkers should be further evaluated.

  • The authors evaluated the clinicopathological/prognostic significance of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), class III β-tubulin (βIII-tubulin), and stathmin-1 or oncoprotein-18 (STMN1).
  • Formalin-fixed, paraffin-embedded tumor specimens from 42 patients were used for analysis of TS, DPD, TP, βIII–tubulin, and STMN1 expression with a real-time reverse transcription-PCR technique.
  • Patients were classified into the high-expression and low-expression groups according to the median value of the expression level of each biomarker.
  • There was a significantly longer time to progression (TTP) in the high-TP group (P=0.018).

  • The multivariate analysis revealed that the TP expression (hazard ratio for the low-TP group vs. the high-TP group, 2.873; 95% confidence interval, 1.143–7.223; P=0.025) is independent of prognostic factors for TTP.
  • In the subgroup of patients treated with capecitabine plus taxanes as first-line chemotherapy, TTP was significantly longer in the low-βIII-tubulin group (P=0.047).
  • The gene expression of TS, DPD, and STMN1 failed to have any significant impact on the outcome.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List